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BACKGROUND
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-
specific antigen (PSA) testing remains uncertain.
METHODS
We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for 
the treatment of clinically localized prostate cancer. Between 1999 and 2009, a total of 
82,429 men 50 to 69 years of age received a PSA test; 2664 received a diagnosis of localized 
prostate cancer, and 1643 agreed to undergo randomization to active monitoring (545 men), 
surgery (553), or radiotherapy (545). The primary outcome was prostate-cancer mortality 
at a median of 10 years of follow-up. Secondary outcomes included the rates of disease 
progression, metastases, and all-cause deaths.
RESULTS
There were 17 prostate-cancer–specific deaths overall: 8 in the active-monitoring group (1.5 
deaths per 1000 person-years; 95% confidence interval [CI], 0.7 to 3.0), 5 in the surgery 
group (0.9 per 1000 person-years; 95% CI, 0.4 to 2.2), and 4 in the radiotherapy group 
(0.7 per 1000 person-years; 95% CI, 0.3 to 2.0); the difference among the groups was not 
significant (P = 0.48 for the overall comparison). In addition, no significant difference was 
seen among the groups in the number of deaths from any cause (169 deaths overall; P = 0.87 
for the comparison among the three groups). Metastases developed in more men in the 
active-monitoring group (33 men; 6.3 events per 1000 person-years; 95% CI, 4.5 to 8.8) 
than in the surgery group (13 men; 2.4 per 1000 person-years; 95% CI, 1.4 to 4.2) or the 
radiotherapy group (16 men; 3.0 per 1000 person-years; 95% CI, 1.9 to 4.9) (P = 0.004 for 
the overall comparison). Higher rates of disease progression were seen in the active-mon-
itoring group (112 men; 22.9 events per 1000 person-years; 95% CI, 19.0 to 27.5) than in 
the surgery group (46 men; 8.9 events per 1000 person-years; 95% CI, 6.7 to 11.9) or the 
radiotherapy group (46 men; 9.0 events per 1000 person-years; 95% CI, 6.7 to 12.0) (P<0.001 
for the overall comparison).
CONCLUSIONS
At a median of 10 years, prostate-cancer–specific mortality was low irrespective of the treat-
ment assigned, with no significant difference among treatments. Surgery and radiotherapy 
were associated with lower incidences of disease progression and metastases than was 
active monitoring. (Funded by the National Institute for Health Research; ProtecT Current 
Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.)
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The management of clinically local-ized prostate cancer that is detected on the basis of prostate-specific antigen (PSA) 
levels remains controversial. In the United States 
alone, an estimated 180,890 cases will be diag-
nosed in 2016, and 26,120 men will die from the 
disease.1 The widespread use of PSA testing has 
resulted in a dramatic increase in the diagnosis 
and treatment of prostate cancer, but many men 
do not benefit from intervention because the dis-
ease is either indolent or disseminated at diag-
nosis. Prostate cancer often progresses slowly, 
and many men die of competing causes. In addi-
tion, interventions for prostate cancer can have 
adverse effects on sexual, urinary, or bowel func-
tion. Two treatment trials have evaluated the 
effectiveness of treatment, but they did not com-
pare the most common contemporary methods: 
surgery, radiotherapy, and monitoring or surveil-
lance.2-4
The National Institute for Health Research–
supported Prostate Testing for Cancer and Treat-
ment (ProtecT) trial recruited men 50 to 69 years 
of age in the United Kingdom. From 1999 to 
2009, a total of 82,429 men had a PSA test; 2664 
received a diagnosis of localized prostate cancer 
(including 146 men from the feasibility study), 
and 1643 agreed to undergo randomization to 
active monitoring, radical prostatectomy, or radio-
therapy. Here we report the effectiveness of each 
intervention in relation to prostate-cancer–spe-
cific mortality and all-cause mortality and the 
incidence of metastases and disease progression 
at a median of 10 years of follow-up in the ran-
domized trial. In a companion article, we report 
complete patient-reported outcomes in the ran-
domized cohort at 6 years of follow-up.5
Me thods
Participants
A total of 545 men were randomly assigned to 
active monitoring, 553 to radical prostatectomy, 
and 545 to radiotherapy. The median age of the 
participants was 62 years (range, 50 to 69), the 
median PSA level at the prostate-check clinic 
was 4.6 ng per milliliter (range, 3.0 to 19.9), 77% 
had tumors with a Gleason score of 6 (on a scale 
from 6 to 10, with higher scores indicating a 
worse prognosis), and 76% had stage T1c dis-
ease; there were no meaningful differences at 
baseline among the three randomized groups.6
Information on baseline demographic and clini-
cal characteristics according to assigned treat-
ment group is provided in Table S2 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.
Trial Design and Oversight
Details of the screening, randomization, and 
follow-up of patients in the ProtecT trial were 
published previously6 and are shown in Fig. 1. 
Approval for the trial was obtained from the 
U.K. East Midlands (formerly Trent) Multicenter 
Research Ethics Committee (01/4/025). The trial 
was overseen by an independent trial steering 
committee and a separate data and safety moni-
toring committee. All the participants provided 
written informed consent. The authors vouch for 
the accuracy and completeness of the data and 
for the fidelity of the trial to the protocol, avail-
able at NEJM.org.
Randomization
Treatment options were discussed with the men, 
and 1643 men (62% of the eligible participants) 
agreed to undergo randomization. Treatment 
assignments were stratified according to site, 
with stochastic minimization to improve the 
balance across the groups with respect to age, 
Gleason score (<7, 7, or 8 to 10 points), and the 
mean of the baseline and first biopsy PSA test 
results together (<6.0, 6.0 to 9.9, or >9.9 ng per 
milliliter). After randomization, clinicians and 
participants were aware of the group assignments.
Treatment Procedures and Clinical 
Management
Clinical management was standardized with the 
use of trial-group–specific pathways. The pur-
pose of active monitoring was to minimize the 
risk of overtreatment by avoiding immediate 
radical intervention and by monitoring disease 
progression regularly, so that radical treatment 
with curative intent could be given as necessary. 
Triggers to reassess patients and consider a 
change in clinical management were based large-
ly on changes in PSA levels. This was very differ-
ent from “watchful waiting” in the Scandinavian 
Prostate Cancer Group Study Number 4 (SPCG-4) 
and in the U.S. Prostate Cancer Intervention 
versus Observation Trial (PIVOT), which had no 
planned protocol for curative radical interven-
tion on disease progression.2,4 Serum PSA levels 
A Quick Take 
is available at 
NEJM.org
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were measured every 3 months in the first year 
and every 6 to 12 months thereafter. Changes in 
PSA levels were assessed. An increase of at least 
50% during the previous 12 months triggered a 
review. Management options included continued 
monitoring or further tests and radical or pallia-
tive treatments as required.
The radiotherapy protocol included neoadjuvant 
androgen-deprivation therapy for 3 to 6 months 
before and concomitantly with three-dimensional 
conformal radiotherapy delivered at a total dose 
of 74 Gy in 37 fractions. The protocol for quality 
assurance followed the RT01 trial procedures.7-9
The trial oncologist held a review appointment 
with participants if PSA levels rose by at least 
2.0 ng per milliliter above the nadir or if con-
cerns were raised about progression. Management 
options included continued monitoring, additional 
testing, salvage therapy, or palliative treatments.
In men assigned to surgery, postoperative PSA 
levels were measured every 3 months for the first 
year, every 6 months for 2 years, and yearly 
thereafter. Adjuvant or salvage radiotherapy was 
discussed with patients who had positive surgi-
cal margins, extracapsular disease, or a post-
operative PSA level of 0.2 ng per milliliter or 
higher. In all groups, androgen-deprivation ther-
apy was offered when PSA levels reached 20 ng 
per milliliter or less, if indicated. Imaging of the 
skeleton was recommended if the PSA level 
reached 10 ng per milliliter.
Clinical Outcome Measures
The primary outcome measure was prostate-
cancer mortality at a median of 10 years of 
follow-up, with prostate-cancer–related deaths 
defined as deaths that were definitely or proba-
bly due to prostate cancer or its treatment. The 
process for ascertaining cause of death was 
adapted from the Prostate, Lung, Colorectal, and 
Ovarian (PLCO) Cancer Screening Trial and the 
European Randomized Study of Screening for 
Figure 1. Randomization, Treatment, and Follow-up.
A total of 88% of the men assigned to active monitoring, 71% of the men assigned to surgery, and 74% of men assigned 
to radiotherapy received the assigned treatment within 9 months after randomization. A total of 14 patients were 
lost to follow-up for secondary outcomes, but data on deaths were captured for all participants.
1643 Underwent randomization
2664 Patients with localized disease
were eligible
482 Started assigned protocol 
within 9 mo
37 Underwent surgery per trial
protocol
17 Received radiotherapy per trial
protocol
2 Received brachytherapy
7 Did not start treatment
6 Were lost to follow-up 3 Were lost to follow-up 5 Were lost to follow-up
545 Were included in primary
analysis
553  Were included in primary
analysis
545 Were included in primary
analysis
405 Started assigned protocol 
within 9 mo
75 Underwent active monitoring
per trial protocol
41 Underwent surgery per trial
protocol
11 Received other treatment
13 Did not start treatment
391 Underwent surgery within
9 mo
95 Underwent active monitoring
per trial protocol 
33 Received radiotherapy
per trial protocol
11 Received other treatment
23 Did not start treatment
545 Were assigned to active
monitoring
545 Were assigned to
radical radiotherapy
553 Were assigned to radical
prostatectomy
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Prostate Cancer (ERSPC).10-12 The independent 
cause-of-death evaluation committee, whose 
members were unaware of the treatment assign-
ments, reviewed summaries of anonymized re-
cords. Deaths were categorized as definitely, 
probably, possibly, probably not, or definitely 
not due to prostate cancer.13,14
Secondary outcomes included all-cause mor-
tality and the rates of metastases, clinical pro-
gression, primary treatment failure, and treatment 
complications. Metastatic disease was defined 
as bony, visceral, or lymph-node metastases on 
imaging or PSA levels above 100 ng per milli-
liter. Patients were considered to have clinical 
progression if they had any of the following: 
evidence of metastases, diagnosis of clinical T3 
or T4 disease, long-term androgen-deprivation 
therapy, ureteric obstruction, rectal fistula, or the 
need for a urinary catheter owing to local tumor 
growth. Primary treatment failure after surgery 
was defined as a PSA level of 0.2 ng per milliliter 
or higher at 3 months after surgery, and primary 
treatment failure after radiotherapy was defined 
according to the Phoenix Consensus Conference 
recommendations.15
Although some events of clinical progression 
such as metastases could be reported uniformly, 
manifestations of local progression could differ 
between men receiving radical treatment and 
those receiving active monitoring because of dif-
ferences in treatment assignments. After surgery, 
the serious intervention-related complications 
that were recorded were death, transfusion of 
more than 3 units of blood, thromboembolic or 
cardiovascular events, rectal injury, and anasto-
motic problems requiring intervention. After ra-
diotherapy, the complications that were recorded 
were death and any treatment-related toxic effect 
resulting in major surgical intervention. Interven-
tion-related complications within 90 days after 
the completion of treatment were recorded.
Statistical Analysis
A prespecified statistical analysis plan was de-
veloped before the data for the primary analysis 
were accessed16 (see the Supplementary Appen-
dix). The primary outcome of prostate-cancer 
mortality (the rate of death due to prostate can-
cer or its treatment) was compared among the 
three assigned treatment groups on an intention-
to-treat basis with the use of Cox proportional-
hazards regression adjusted for trial center, age 
at baseline, Gleason score, and PSA level at base-
line (log-transformed). The results of an alterna-
tive cumulative-incidence approach with com-
peting risks regression are shown in Figs. S1 
and S2 and Table S1 in the Supplementary Ap-
pendix. Prostate-cancer–specific mortality is re-
ported with 95% confidence intervals for each 
treatment group, and pairwise significance tests 
were planned if a test of the null hypothesis of 
no difference in 10-year disease-specific risk of 
death across all three groups yielded a P value 
of less than 0.05. This conditional approach was 
designed to keep the overall false positive rate at 
5%.17 The primary analysis approach was adapt-
ed as necessary for secondary outcomes. Four 
prespecified subgroup analyses were conducted 
with the use of relevant interaction terms: age, 
clinical stage, Gleason score, and PSA level. All 
analyses were conducted with the use of Stata 
software, version 14.1 (StataCorp).
R esult s
Adherence to Assigned Treatment  
and Primary Treatment Failure
Of the 1643 men who underwent randomization 
(Fig. 1), 14 (1%) were lost to follow-up for sec-
ondary outcomes during the 10-year follow-up 
period, but data on deaths were captured for all 
participants. A total of 482 of the 545 men as-
signed to active monitoring (88%), 391 of the 
553 men assigned to surgery (71%), and 405 of 
the 545 men assigned to radiotherapy (74%) re-
ceived the assigned treatment within 9 months 
after randomization.
Fig. 2 shows the cumulative probability of 
receiving radical treatment. By the end of our 
reported follow-up, more than 85% of the men 
assigned to radiotherapy or surgery had received 
a radical intervention. Of the 545 men assigned 
to active monitoring, 291 had received a radical 
treatment by the end of November 2015 (Kaplan–
Meier estimate, 54.8%; 95% confidence interval 
[CI], 50.4 to 59.3). Of those 291 men, 142 (49%) 
underwent surgery (37 within 9 months after 
assignment to the active-monitoring group), 97 
(33%) received per-protocol radiotherapy (17 with-
in 9 months after group assignment), and 22 (8%) 
received brachytherapy (2 within 9 months after 
group assignment); in addition, 27 (9%) received 
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nonprotocol radiotherapy, and 3 (1%) received 
high-intensity focused ultrasound therapy, all 
beyond 9 months after group assignment.
Of the 391 men who underwent prostatecto-
my, 18 had primary treatment failure. Of those, 
9 (2%) had a PSA level of 0.2 ng per milliliter 
or higher between 31 and 183 days after surgery; 
5 received salvage radiotherapy and 1 long-term 
androgen-deprivation therapy within a year after 
surgery. An additional 9 men received adjuvant 
radiotherapy within a year after surgery, because 
of pathologic extracapsular (pT3) disease (8 men) 
or positive surgical margins (7 men). Stage pT3 
disease was present in 114 of the 391 men (29%), 
and 93 (24%) had a positive surgical margin. 
Four of the 280 patients who underwent lymph-
adenectomy (1%) had lymph-node involvement. 
Of the 405 men who started radiotherapy within 
9 months after treatment assignment, 55 (14%) 
had an increase in the PSA level of 2 ng per milli-
liter or more above the nadir after radiotherapy, 
of whom 3 underwent salvage prostatectomy, 14 
received long-term androgen-deprivation therapy, 
and 1 received high-intensity focused ultrasound 
therapy.
Prostate-Cancer–Specific and All-Cause 
Mortality
The independent cause-of-death evaluation com-
mittee ascertained seven definite and one prob-
able prostate-cancer–specific deaths in the active-
monitoring group, three definite and two probable 
prostate-cancer deaths in the surgery group, and 
four definite prostate-cancer deaths in the radio-
therapy group (Table 1 and Fig. 3A). Prostate-
cancer–specific survival was at least 98.8% in all 
groups, and there was no significant difference 
among the three randomized groups (P = 0.48 by 
log-rank test). Hazard ratios for prostate-cancer–
specific death were as follows: 0.51 (95% CI, 
0.15 to 1.69) for the comparison of the radio-
therapy group with the active-monitoring group; 
0.80 (95% CI, 0.22 to 2.99) for the comparison 
of the radiotherapy group with the surgery group; 
and 0.63 (95% CI, 0.21 to 1.93) for the compari-
son of the surgery group with the active-monitor-
ing group. There was no evidence that between-
group differences in prostate-cancer mortality 
varied according to age, PSA level, Gleason score, 
or clinical stage (Table 2). Deaths from any 
cause were evenly distributed across the treat-
ment groups (P = 0.87 by likelihood-ratio test) 
(Table 1, and Table S3 in the Supplementary Ap-
pendix), although the confidence intervals for the 
hazard ratios were wide and so did not provide 
strong evidence of equivalence across the groups 
(Table S1 in the Supplementary Appendix). De-
tails of the men who died of prostate cancer are 
provided in Table S4 in the Supplementary Ap-
pendix.
Disease Progression
A total of 204 men had disease progression, in-
cluding metastases (Table 1 and Fig. 3B). The 
incidence was higher in the active-monitoring 
group than in the surgery and radiotherapy 
groups (112 men in the active-monitoring group, 
46 in the surgery group, and 46 in the radio-
therapy group; P<0.001 for the overall compari-
son). Evidence of disease progression included 
the presence of metastases (33 men in the active-
monitoring group, 13 in the surgery group, and 
16 in the radiotherapy group; P = 0.004 for the 
overall comparison), clinical T3 or T4 disease 
(79 men in the active-monitoring group, 24 in 
the surgery group, and 21 in the radiotherapy 
group), and the initiation of long-term androgen-
deprivation therapy (47 men in the active-monitor-
Figure 2. Kaplan–Meier Estimates of the Cumulative Probability
of Undergoing Radical Intervention during the Follow-up Period,
According to Treatment Group.
Radical intervention was defined as radical prostatectomy, per-protocol 
 radiotherapy, nonprotocol radiotherapy (including brachytherapy), or high- 
intensity focused ultrasound therapy.
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ing group, 26 in the surgery group, and 30 in the 
radiotherapy group), with evidence of more than 
one criterion for some men.
Treatment Complications
There were no deaths related to surgery; 9 men 
had thromboembolic or cardiovascular events, 
14 required transfusion of more than 3 units of 
blood, 1 had a rectal injury, and 9 required in-
tervention for anastomotic problems. There were 
3 deaths unrelated to prostate cancer within 90 
days after the completion of radiotherapy.
Numbers Needed to Treat
On the basis of our results, we estimated that 27 
men would need to be treated with prostatecto-
my rather than receive active monitoring to avoid 
1 patient having metastatic disease, and 33 men 
would need to be treated with radiotherapy 
rather than receive active monitoring to avoid 
1 patient having metastatic disease. A total of 
9 men would need to be treated with either pros-
tatectomy or radiotherapy to avoid 1 patient hav-
ing clinical progression.
Sensitivity Analyses
We conducted sensitivity analyses that excluded 
men who were recruited during the feasibility 
phase or that included deaths that were judged 
to be possibly due to prostate cancer. The find-
ings were similar to those in the primary 
analysis.
Variable
Active Monitoring
(N=545)
Surgery
(N =553)
Radiotherapy
(N =545) P Value*
Prostate-cancer mortality
Total person-yr in follow-up 5393 5422 5339
No. of deaths due to prostate cancer† 8 5 4
Prostate-cancer–specific survival — % (95% CI)†
At 5 yr 99.4 (98.3–99.8) 100 100
At 10 yr 98.8 (97.4–99.5) 99.0 (97.2–99.6) 99.6 (98.4–99.9)
Prostate-cancer deaths per 1000 person-yr (95% CI)† 1.5 (0.7–3.0) 0.9 (0.4–2.2) 0.7 (0.3–2.0) 0.48
Incidence of clinical progression‡
Person-yr of follow-up free of clinical progression 4893 5174 5138
No. of men with clinical progression 112 46 46
Clinical progression per 1000 person-yr (95% CI) 22.9 (19.0–27.5) 8.9 (6.7–11.9) 9.0 (6.7–12.0) <0.001
Incidence of metastatic disease
Person-yr of follow-up free of metastatic disease 5268 5377 5286
No. of men with metastatic disease 33 13 16
Metastatic disease per 1000 person-yr (95% CI) 6.3 (4.5–8.8) 2.4 (1.4–4.2) 3.0 (1.9–4.9) 0.004
All-cause mortality
Total person-yr in follow-up 5393 5422 5339
No. of deaths due to any cause 59 55 55
All-cause deaths per 1000 person-yr (95% CI) 10.9 (8.5–14.1) 10.1 (7.8–13.2) 10.3 (7.9–13.4) 0.87
*  P values were calculated with the use of a log-rank test of the null hypothesis of no difference in effectiveness across the three treatments. 
The planned adjusted analysis was not possible owing to the low number of events.
†  Deaths due to prostate cancer were defined as deaths that were definitely or probably due to prostate cancer or its treatment, as determined 
by the independent cause-of-death evaluation committee.
‡  Disease progression was defined as death due to prostate cancer or its treatment; evidence of metastatic disease; long-term androgen- 
deprivation therapy; clinical T3 or T4 disease; and ureteric obstruction, rectal fistula, or the need for a permanent catheter when these are 
not considered to be a complication of treatment.
Table 1. Prostate-Cancer Mortality, Incidence of Clinical Progression and Metastatic Disease, and All-Cause Mortality, According to
Randomized Treatment Group.
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Discussion
The ProtecT trial was designed to evaluate the 
effectiveness of the three major contemporary 
treatment approaches to reducing prostate-can-
cer mortality and improving clinical outcomes 
in men with PSA-detected clinically localized 
disease. The results show that death from pros-
tate cancer in such men remained low at a me-
dian of 10 years of follow-up, at approximately 
1%, irrespective of the treatment assigned, a rate 
that is considerably lower than was anticipated 
when the trial commenced. All-cause mortality 
was also low — at approximately 10%. The rate 
of disease progression among men assigned to 
prostatectomy or radiotherapy was less than half 
the rate among men assigned to active monitor-
ing (P<0.001 for the overall comparison), as was 
the rate of metastatic disease (P = 0.004 for the 
overall comparison). These differences show the 
effectiveness of immediate radical therapy over 
active monitoring, but they have not translated 
into significant differences — nor have they 
ruled out equivalence — in disease-specific or 
all-cause mortality; thus, longer-term follow-up 
is necessary. The majority of men who were ran-
domly assigned to active monitoring (88%) ac-
cepted their treatment assignment, but a quarter 
of them received radical treatment within 3 years 
after their initial assignment and over half by 
10 years.
SPCG-4 showed that the risk of death from 
cancer was 6.6 percentage points lower within 
8 years (average follow-up) in the group assigned 
to surgery than in the group assigned to watch-
ful waiting and 11.0 percentage points lower 
within 23 years.2,3 Only 10% of the men in 
SPCG-4 had prostate cancer detected by measure-
ment of PSA levels. The ProtecT trial findings 
were similar to those of PIVOT in that prostatec-
tomy did not result in lower all-cause or prostate-
cancer–specific mortality than observation through 
at least 12 years of follow-up.4 All-cause and 
prostate-cancer–specific mortality were much 
lower in the ProtecT trial than in SPCG-4 or 
PIVOT (Table S5 in the Supplementary Appen-
dix). This may have been related to recruitment 
of a healthier cohort through the population-
based PSA-testing program in the ProtecT trial 
and improvements in the medical treatment of 
nonprostatic diseases and of progressing pros-
tate cancer with second-generation and third-
generation androgen-deprivation therapy, bone-
targeted agents (e.g., radionuclides, inhibitors of 
receptor activator of nuclear factor-κβ ligand 
[RANKL], and chemotherapy), and immuno-
therapy. It is likely that this evolution contrib-
uted to the low prostate-cancer mortality in the 
ProtecT trial and will influence future follow-up. 
Figure 3. Kaplan–Meier Estimates of Prostate-Cancer–Specific Survival
and Freedom from Disease Progression, According to Treatment Group.
Panel A shows the rate of prostate-cancer–specific survival. Prostate-cancer–
specific deaths were those that were definitely or probably due to prostate 
cancer or its treatment, as determined by an independent cause-of-death 
evaluation committee whose members were unaware of the treatment as-
signments. Panel B shows the rate of freedom from disease progression. 
Clinical progression of prostate cancer included metastasis and death due 
to prostate cancer or its treatment.
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Evidence of the effectiveness of immediate radi-
cal intervention in reducing disease progression 
was consistent in the ProtecT trial, SPCG-4, and 
PIVOT, with the ProtecT trial showing a similar 
benefit from radiotherapy and surgery.
The PLCO Cancer Screening Trial showed no 
beneficial effect of screening for prostate cancer, 
but this trial had severe limitations because of 
high levels of contamination.10,18,19 In contrast, 
ERSPC showed that screening was associated 
with increased survival and decreased progres-
sion but at a substantial cost of overdetection 
and overtreatment.12,20,21 Synthesizing these data, 
the U.S. Preventive Services Task Force recom-
mended that population screening for prostate 
cancer should not be adopted as a public health 
policy, because risks appeared to outweigh ben-
efits from detecting and treating PSA-detected 
disease.22 The Cluster Randomised Trial of PSA 
Testing for Prostate Cancer (CAP) is assessing 
the effectiveness of population-based PSA testing. 
In this trial, primary care physician practices 
were randomly assigned to enroll participants 
in the ProtecT trial (the intervention group) or to 
follow usual care (the control group receiving no 
formal PSA testing), with prostate-cancer mor-
tality as the primary outcome.23
Primary treatment failure occurred in 18 men 
in the surgery group and in 55 men in the radio-
therapy group. Radical interventions were received 
by 291 men in the active-monitoring group, with 
56 (19%) receiving treatment within 9 months 
after randomization. Between-group comparisons 
with respect to treatment failure require consid-
erable caution because of the different defini-
tions and variables used. In the case of prostatec-
tomy, primary treatment failure can be inferred 
at an early stage because of detectable PSA 
postoperatively. In the case of radiotherapy, treat-
ment failure can be determined only from sub-
sequent increases in PSA levels that might occur 
much later. For patients assigned to active moni-
toring, a change of management to radical treat-
ment might have been undertaken for reasons 
other than disease progression. Rates of change 
of management in the ProtecT trial were similar 
to those in other active surveillance programs.24-26
Between-group comparisons with respect to 
disease progression should also be interpreted 
carefully because of different definitions and 
methods of ascertainment. In the surgery group, 
extracapsular extension (pT3 disease) was pres-
ent in 29% of the men at the time of surgery, a 
proportion of whom could have been cured by the 
radical intervention. Similar rates of an increase 
in clinical stage would be anticipated in the radio-
therapy and active-monitoring groups, emerging 
later as disease progression.
Guidelines suggest that men with low-volume, 
low-risk disease should be followed without im-
mediate intervention.27 Active surveillance in such 
cohorts over a period of 15 years has yielded a 
disease-specific mortality of 0.1 to 1.5%, depend-
ing on the definition of low-risk or very-low-risk 
disease.24,25 However, there remains little consen-
sus about the best protocols for following these 
patients safely, in order to maintain them in a 
Variable No. of Deaths Due to Prostate Cancer† P Value‡
Active 
Monitoring 
(N = 545)
Surgery 
(N = 553)
Radiotherapy 
(N = 545)
Age at randomization 0.09
<65 yr 1 3 1
≥65 yr 7 2 3
PSA level at diagnosis 0.72
<6 ng/ml 5 3 4
≥6 ng/ml 3 2 0
Gleason score at 
 diagnosis§
0.69
6 3 3 2
≥7 5 2 2
Clinical stage at 
 diagnosis¶
0.95
T1c 5 3 3
T2 3 2 1
*  PSA denotes prostate-specific antigen.
†  Deaths due to prostate cancer were defined as deaths that were definitely or 
probably due to prostate cancer or its treatment, as determined by the inde-
pendent cause-of-death evaluation committee.
‡  P values were calculated with the use of a likelihood-ratio interaction test of 
the null hypothesis of no difference in the relative effectiveness of the three 
treatments across the subgroup levels.
§  Gleason scores range from 6 to 10, with higher scores indicating a more ag-
gressive form of prostate cancer and a worse prognosis.
¶  Stage T1c disease is prostate cancer that is identified by needle biopsy because 
of an elevated PSA level. Stage T2 disease is prostate cancer that is confined 
within the gland, present in one or both lobes by needle biopsy, and palpable 
by digital rectal examination or visible by imaging.
Table 2. Deaths from Prostate Cancer, According to Subgroup.*
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“window of curability.”28 In the ProtecT active-
monitoring group, almost half the men received 
no intervention during the 10-year follow-up 
period.
There are several limitations of the ProtecT 
trial. First, the protocol was developed almost 
two decades ago; since then, treatments and 
diagnostic techniques for prostate cancer have 
evolved. The ProtecT trial did not use multipara-
metric magnetic resonance imaging to evaluate 
patients at diagnosis or during monitoring. Sur-
gical techniques have changed with robot-assisted 
laparoscopic prostatectomy, and although all pa-
tients in the radiotherapy group received neoad-
juvant androgen-deprivation therapy with three-
dimensional conformal irradiation, new techniques 
such as intensity-modulated radiotherapy have 
been introduced, and brachytherapy was not in-
cluded. Second, less than 1% of the participants 
enrolled in this trial were of African–Caribbean 
ancestry (Table S2 in the Supplementary Appen-
dix), but this percentage reflected the population 
in the recruiting centers who were in the trial 
age range.29 The strengths of the trial include 
the randomized comparison of men with PSA-
detected prostate cancer, the inclusion of radio-
therapy, standardized treatment pathways, and 
regular follow-up with high rates of response.
At a median follow-up of 10 years, the ProtecT 
trial showed that mortality from prostate cancer 
was low, irrespective of treatment assignment. 
Prostatectomy and radiotherapy were associated 
with lower rates of disease progression than ac-
tive monitoring; however, 44% of the patients 
who were assigned to active monitoring did not 
receive radical treatment and avoided side ef-
fects.5 Men with newly diagnosed, localized pros-
tate cancer need to consider the critical trade-off 
between the short-term and long-term effects of 
radical treatments on urinary, bowel, and sexual 
function and the higher risks of disease progres-
sion with active monitoring, as well as the ef-
fects of each of these options on quality of life. 
Further follow-up of the ProtecT participants 
with longer-term survival data will be crucial to 
evaluate this trade-off in order to fully inform 
decision making for physicians and patients con-
sidering PSA testing and treatment options for 
clinically localized prostate cancer.
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